Fertility solutions provider Ovum Health has joined forces with IBM Watson to enhance appointment management and access to patient information.
Alice Crisci, a healthcare activist, cancer survivor, mother, and founder of MedAnswers and its telemedicine spinout, Ovum Health is aiming to increase family-building solutions, including pre-pregnancy, prenatal, and postnatal healthcare through digital services.
According to Ovum Health it needed an artificial intelligence (AI) solution to advance its digital offering and turned to the IBM Ecosystem and IBM Watson Assistant.
The partnership between Ovum Health and IBM Watson will utilise each other’s tech and build an international digital service with embed Watsonx Assistant for their mobile app and website called FertilityAnswer Bot. The chat bot will streamline fertility questions and answers to enhance the patients experience. It also has a scheduling feature to allow patients to book medical appointments at the click of a button.
The IBM-powered bot includes 150 questions and answers from Ovum Health’s content library of 18,000 user-generated questions. Backed by clinically validated responses from reproductive experts. Currently there are over 67,000 registered users of the FertilityAnswer Bot across both iOS and Android systems.
IBM will also help Ovum Health identify the return on investment (ROI) of incorporating IBM’s AI technology into their products and services.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThere have been recent technology and device developments in the reproductive health market such as sperm diagnostic systems and other in vitro fertilization (IVF) treatments.
According to GlobalData, the global market for reproductive health devices is forecast to approach sales of $3.7bn by 2030.